デフォルト表紙
市場調査レポート
商品コード
1243334

ヘモグロビノパチーの世界市場

Hemoglobinopathies

出版日: | 発行: Global Industry Analysts, Inc. | ページ情報: 英文 192 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.56円
ヘモグロビノパチーの世界市場
出版日: 2023年03月01日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 192 Pages
納期: 即日から翌営業日
● ご注意事項
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

ヘモグロビノパチーの世界市場は2030年までに13億米ドルに達する

COVID-19後の変化したビジネス環境において、2022年に7億5,790万米ドルと推定されるヘモグロビノパチーの世界市場は、2030年までに13億米ドルの改定規模に達し、2022年から2030年にかけてCAGR 7.1%で成長すると予測しています。本レポートで分析したセグメントの1つである鎌状赤血球症は、CAGR6.8%を記録し、分析期間終了時には7億1,620万米ドルに達すると予測されます。パンデミック後の回復を考慮し、ベータサラセミア分野の成長は、今後8年間のCAGRが7.3%に修正されました。

米国市場は2億2,860万米ドル、中国はCAGR6.7%で成長すると予測される

米国のヘモグロビノパチー市場は、2022年に2億2,860万米ドルと推定されます。世界第2位の経済大国である中国は、2022年から2030年にかけてのCAGRが6.7%で、2030年には2億2,780万米ドルの市場規模に達すると予測されています。その他の注目すべき地域市場としては、日本とカナダがあり、2022年から2030年にかけてそれぞれ6.8%と5.7%の成長が予測されています。欧州では、ドイツがCAGR5.8%で成長すると予測されています。

調査対象企業の例

  • Abbott Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Mindray Medical International Ltd.
  • Nexcelom Bioscience LLC
  • Nihon Kohden Corporation
  • PerkinElmer, Inc.
  • Siemens Healthineers
  • Sysmex Europe GmbH

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP12343

What`s New for 2023?

»Special coverage on Russia-Ukraine war; global inflation; easing of "zero-Covid" policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.

»Global competitiveness and key competitor percentage market shares

» Market presence across multiple geographies - Strong/Active/Niche/Trivial

»Online interactive peer-to-peer collaborative bespoke updates

»Access to our digital archives and MarketGlass Research Platform

»Complimentary updates for one year

Looking Ahead to 2023

The global economy is at a critical crossroads with a number of interlocking challenges and crises running in parallel. The uncertainty around how Russia`s war on Ukraine will play out this year and the war`s role in creating global instability means that the trouble on the inflation front is not over yet. Food and fuel inflation will remain a persistent economic problem. Higher retail inflation will impact consumer confidence and spending. As governments combat inflation by raising interest rates, new job creation will slowdown and impact economic activity and growth. Lower capital expenditure is in the offing as companies go slow on investments, held back by inflation worries and weaker demand. With slower growth and high inflation, developed markets seem primed to enter into a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path poses a real risk of the world experiencing more acute supply chain pain and manufacturing disruptions this year. Volatile financial markets, growing trade tensions, stricter regulatory environment and pressure to mainstream climate change into economic decisions will compound the complexity of challenges faced. Year 2023 is expected to be tough year for most markets, investors and consumers. Nevertheless, there is always opportunity for businesses and their leaders who can chart a path forward with resilience and adaptability.

Global Hemoglobinopathies Market to Reach $1.3 Billion by 2030

In the changed post COVID-19 business landscape, the global market for Hemoglobinopathies estimated at US$757.9 Million in the year 2022, is projected to reach a revised size of US$1.3 Billion by 2030, growing at aCAGR of 7.1% over the period 2022-2030. Sickle Cell Disease, one of the segments analyzed in the report, is projected to record 6.8% CAGR and reach US$716.2 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Beta Thalassemia segment is readjusted to a revised 7.3% CAGR for the next 8-year period.

The U.S. Market is Estimated at $228.6 Million, While China is Forecast to Grow at 6.7% CAGR

The Hemoglobinopathies market in the U.S. is estimated at US$228.6 Million in the year 2022. China, the world`s second largest economy, is forecast to reach a projected market size of US$227.8 Million by the year 2030 trailing a CAGR of 6.7% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 6.8% and 5.7% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 5.8% CAGR.

Select Competitors (Total 38 Featured) -

  • Abbott Diagnostics
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • Mindray Medical International Ltd.
  • Nexcelom Bioscience LLC
  • Nihon Kohden Corporation
  • PerkinElmer, Inc.
  • Siemens Healthineers
  • Sysmex Europe GmbH

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Hemoglobinopathy - Global Key Competitors Percentage Market Share in 2022 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2022 (E)
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Hemoglobinopathies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Hemoglobinopathies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 3: World 16-Year Perspective for Hemoglobinopathies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2023 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Sickle Cell Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Sickle Cell Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 6: World 16-Year Perspective for Sickle Cell Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Beta Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Beta Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 9: World 16-Year Perspective for Beta Thalassemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Alpha Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Alpha Thalassemia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 12: World 16-Year Perspective for Alpha Thalassemia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 15: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Diagnostics Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Diagnostics Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 18: World 16-Year Perspective for Diagnostics Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 21: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2023 & 2030
    • TABLE 22: World Hemoglobinopathies Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2023 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2023 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2023 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2023 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2023 & 2030
  • JAPAN
    • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2023 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2023 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2023 & 2030
  • CHINA
    • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2023 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 43: China 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2023 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 46: China 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2023 & 2030
  • EUROPE
    • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2023 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Hemoglobinopathies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2022 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Hemoglobinopathies by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Hemoglobinopathies by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2023 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2023 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2023 & 2030
  • FRANCE
    • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2023 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 58: France 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2023 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 61: France 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2023 & 2030
  • GERMANY
    • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2023 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2023 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2023 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2023 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2023 & 2030
  • UNITED KINGDOM
    • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2023 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2023 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2023 & 2030
  • REST OF EUROPE
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 81: Rest of Europe Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 82: Rest of Europe 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2023 & 2030
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 85: Rest of Europe 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2023 & 2030
  • ASIA-PACIFIC
    • Hemoglobinopathies Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2023 (E)
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 88: Asia-Pacific 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2023 & 2030
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 91: Asia-Pacific 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2023 & 2030
  • REST OF WORLD
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 93: Rest of World Historic Review for Hemoglobinopathies by Indication - Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 94: Rest of World 16-Year Perspective for Hemoglobinopathies by Indication - Percentage Breakdown of Value Sales for Sickle Cell Disease, Beta Thalassemia and Alpha Thalassemia for the Years 2014, 2023 & 2030
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics - Independent Analysis of Annual Sales in US$ Thousand for the Years 2022 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Hemoglobinopathies by End-Use - Hospitals, Diagnostics Laboratories and Clinics Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2021 and % CAGR
    • TABLE 97: Rest of World 16-Year Perspective for Hemoglobinopathies by End-Use - Percentage Breakdown of Value Sales for Hospitals, Diagnostics Laboratories and Clinics for the Years 2014, 2023 & 2030

IV. COMPETITION